高灵敏度基因分型检测KRAS、NRAS、BRAF和PIK3CA以超选择转移性结直肠癌患者接受帕尼单抗联合FOLFIRI的II期研究:ULTRA试验
该单臂II期试验纳入72例伊立替康耐药的转移性结直肠癌患者,采用高灵敏度数字PCR检测KRAS、NRAS、BRAF和PIK3CA突变,评估帕尼单抗联合FOLFIRI的疗效。数字PCR检出RAS突变23例(32%)、RAS/BRAF突变25例(35%),高于定量PCR的7例(10%)和11例(15%)。5%突变截断值下野生型患者获得最高ORR、PFS和OS,作者结论认为数字PCR未改善定量PCR的预测性能,低频突变等位基因的生物学和临床意义需进一步研究。
要点
- 数字PCR检出RAS突变23例(32%)、RAS/BRAF突变25例(35%),定量PCR仅7例(10%)和11例(15%)。
- 5%突变截断值下野生型患者ORR、PFS和OS最高,突变患者最低。
- 作者结论认为数字PCR未改善定量PCR的预测性能,低频突变等位基因的意义需进一步研究。
核心结论
- 高灵敏度数字PCR可准确识别KRAS、NRAS、BRAF和PIK3CA突变。
- 作者结论认为预测结局的最佳RAS/BRAF突变截断值为5%,这解释了数字PCR未能改善定量PCR的预测性能。
- 作者认为低频突变等位基因的生物学和临床意义需进一步研究。
研究设计与样本
- 单臂II期试验,分析伊立替康耐药转移性结直肠癌患者肿瘤组织中38个KRAS、NRAS、BRAF和PIK3CA热点突变。
- 患者接受帕尼单抗联合FOLFIRI治疗直至疾病进展或提前退出。
- 突变谱通过纳流控数字PCR识别,并与临床结局(ORR、PFS、OS)在0%至5%截断值下进行相关性分析,同时进行定量PCR分析。
- 共纳入72例可评估患者。
主要发现
- 数字PCR检出RAS(KRAS/NRAS)突变23例(32%),RAS/BRAF突变25例(35%);定量PCR分别检出7例(10%)和11例(15%)。
- 数字PCR检出PIK3CA突变2例(3%),定量PCR检出1例(1%),未纳入分析。
- 采用不同数字PCR截断值进行RAS和RAS/BRAF分析,产生不同的临床结局。
- 5%截断值下,野生型患者获得最高ORR、PFS和OS,突变患者获得最低值。
- 定量PCR定义的RAS/BRAF野生型和突变型患者观察到相似结局。
临床怎么用
- 作者结论认为预测结局的最佳RAS/BRAF突变截断值为5%。
- 作者结论认为数字PCR未改善定量PCR的预测性能。
- 作者认为低频突变等位基因的生物学和临床意义需进一步研究。
局限性
- 作者结论指出低频突变等位基因的生物学和临床意义需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of patients using a high-sensitive digital PCR (dPCR) to determine KRAS, NRAS, BRAF and PIK3CA status can improve clinical outcomes of panitumumab plus FOLFIRI. PATIENTS AND METHODS: This was a single-arm phase II trial that analysed 38 KRAS, NRAS, BRAF and PIK3CA hotspots in tumour tissues of irinotecan-resistant metastatic colorectal cancer patients who received panitumumab plus FOLFIRI until disease progression or early withdrawal. Mutation profiles were identified by nanofluidic dPCR and correlated with clinical outcomes (ORR, overall response rate; PFS, progression-free survival; OS, overall survival) using cut-offs from 0% to 5%. A quantitative PCR (qPCR) analysis was also performed. RESULTS: Seventy-two evaluable patients were enrolled. RAS (KRAS/NRAS) mutations were detected in 23 (32%) patients and RAS/BRAF mutations in 25 (35%) by dPCR, while they were detected in 7 (10%) and 11 (15%) patients, respectively, by qPCR. PIK3CA mutations were not considered in the analyses as they were only detected in 2 (3%) patients by dPCR and in 1 (1%) patient by qPCR. The use of different dPCR cut-offs for RAS (KRAS/NRAS) and RAS/BRAF analyses translated into differential clinical outcomes. The highest ORR, PFS and OS in wild-type patients with their lowest values in patients with mutations were achieved with a 5% cut-off. We observed similar outcomes in RAS/BRAF wild-type and mutant patients defined by qPCR. CONCLUSIONS: High-sensitive dPCR accurately identified patients with KRAS, NRAS, BRAF and PIK3CA mutations. The optimal RAS/BRAF mutational cut-off for outcome prediction is 5%, which explains that the predictive performance of qPCR was not improved by dPCR. The biological and clinical implications of low-frequent mutated alleles warrant further investigations. CLINICALTRIALS.GOV NUMBER: NCT01704703. EUDRACT NUMBER: 2012-001955-38.
引用
- Santos C, Azuara D, Viéitez JM, et al. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Ann Oncol. 2019. PMID: 30840064. doi:10.1093/annonc/mdz082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。